Report
2013 Performance and Accountability Report
Date
File
2013 Performance and Accountability Report
(18.75 MB)
Displaying 3141 - 3160 of 4946
1312005 Informal Interpretation
Date
Rule
801.1
1) If B is acquired directly by A, there is no acquiring person, so not reportable. 2) If B is acquired by a sub of A that is not itself an agency of the state, the sub would be its own UPE and the...
File
Original Image File
(481.52 KB)
Professional Associations Settle FTC Charges by Eliminating Rules That Restricted Competition Among Their Members
Date
Two professional associations, of music teachers and legal support services providers respectively, have agreed to eliminate provisions in their codes of ethics that limited competition among their...
1312002 Informal Interpretation
Date
Rule
802.3, 801.40
Agree that the sales meters are the appropriate meters to use in the 802.3 analysis. K Walsh concurs.
File
Original Image File
(258.14 KB)
1312004 Informal Interpretation
Date
Rule
801.1
The key is date of closing.
File
Original Image File
(104.56 KB)
FTC Approves Final Order Settling Charges that Actavis, Inc.’s Acquisition of Warner Chilcott plc Would Be Anticompetitive in Four Current and Future Drug Markets
Date
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Actavis, Inc’s proposed acquisition of Warner Chilcott plc would reduce competition in...
Actavis, Inc. and Warner Chilcott PLC, In the Matter of
Under a settlement, the FTC required Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.The settlement protects competition in the markets for 21 current and future generic drugs, used to treat a wide range of conditions ranging from hypertension and diabetes to anxiety and attention deficit hyperactivity disorder (ADHD).
Type of Action
Administrative
Last Updated
FTC Matter/File Number
131 0152
Docket Number
C-4414
FTC Postpones Follow-On Biologics Workshop Due to Inclement Weather
Date
Due to inclement weather and the closure of the federal government for today, the Federal Trade Commission has postponed until further notice its one-day public workshop on Follow-On Biologics: Impact...
FTC Launches Redesigned FTC.gov Website
Date
The Federal Trade Commission today launched a redesigned FTC.gov website that’s easier to use and reader friendly on tablets and smart phones. Users can now sort FTC cases, early termination notices...
1312001 Informal Interpretation
Date
Rule
801.10, 801.11
Agree.
File
Original Image File
(224.09 KB)
FTC Announces Agenda for Workshop Examining Competition Issues Surrounding Biologic and Follow-on Biologic Medicines: Biosimilars and Interchangeables
Date
The Federal Trade Commission has announced the agenda for the upcoming public roundtable on “Follow-on Biologics: Impact of Recent Legislative and Regulatory Naming Proposals on Competition.” The...
FTC Staff Submits Comment to the Commission on Dental Accreditation Regarding its Proposed Standards for Dental Therapy Education Programs
Date
Federal Trade Commission staff submitted a comment to the American Dental Association’s Commission on Dental Accreditation (CODA) regarding CODA’s proposed Accreditation Standards for Dental Therapy...
Supplemental Materials of Maureen K. Ohlhausen on “The FTC at 100: Where Do We Go From Here?”
Date
By
Maureen K. Ohlhausen, Former Commissioner and Former Acting Chair
Statement of Commissioner Julie Brill on The FTC at 100: Where Do We Go from Here?
Date
By
Julie Brill, Former Commissioner
RELATED TESTIMONY: Prepared Statement of the Federal Trade Commission On "The FTC At 100: Where Do We Go From Here?" (December 3, 2013)
Prepared Statement of the Federal Trade Commission On "The FTC At 100: Where Do We Go From Here?"
Date
By
Edith Ramirez, Former Chairwoman;
Julie Brill, Former Commissioner;
Maureen K. Ohlhausen, Former Commissioner and Former Acting Chair;
Joshua D. Wright, Former Commissioner
Prepared Statement of the Federal Trade Commission On "The FTC At 100: Where Do We Go From Here?" – Before the Subcommittee on Commerce, Manufacturing, and Trade of the Committee on Energy and...
Statement of Chairwoman Edith Ramirez on “The FTC at 100”
Date
By
Edith Ramirez, Former Chairwoman
RELATED TESTIMONY: Prepared Statement of the Federal Trade Commission On "The FTC At 100: Where Do We Go From Here?" (December 3, 2013)
File
FTC Testifies on Its Work to Protect Consumers and Promote Competition As the Agency Approaches Its 100th Anniversary
Date
The Federal Trade Commission testified before Congress on the agency’s long track record of protecting consumers and promoting competition in the U.S. economy, as well as the agency’s ongoing work and...
Displaying 3141 - 3160 of 4946